AI reads lung cancer scans to predict best treatment

NCT ID NCT07449858

Ongoing Knowledge-focused Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether computer analysis of PET/CT scans can help doctors more accurately stage non-small cell lung cancer and predict genetic mutations. Researchers will use data from 500 patients to build and test machine learning models. The goal is to provide better, personalized treatment guidance without needing extra invasive tests.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to more accurate, non-invasive ways to stage lung cancer and predict gene mutations, helping doctors choose the best treatment for each patient.
What could go wrong: This is a retrospective study using existing data, not a clinical trial testing a new treatment. The models may not work as well in real-world settings or for all patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Guangdong Second Provincial General Hospital

Guangzhou, Guangdong, 510317, China
The First Hospital of China Medical University

Shenyang, Liaoning, 110001, China
The Second Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310009, China
West China Hospital of Sichuan University

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.